Skip to main
NVCR

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 17%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

NovoCure Ltd has demonstrated positive financial momentum with a reported 4Q25 revenue of $174.4 million, reflecting a 4% sequential increase and an 8% year-over-year improvement, contributing to a full-year revenue of $655.4 million for 2025. The company has seen an 8% growth in Optune Lua prescriptions for Non-small cell lung cancer, bolstered by national reimbursement in Spain, which is anticipated to further enhance revenue in 2026. Overall, continued growth in the U.S. market, supported by robust sales dynamics and ongoing clinical trials, augurs well for NovoCure’s financial future.

Bears say

NovoCure Ltd faces a negative outlook primarily due to a decrease in revenue estimates, with projections for Glioblastoma revenue reduced from $702 million to $690 million and total revenue revised down from $738.9 million to $711.3 million for 2026. Challenges in market adoption and commercialization efforts for its products, particularly the Optune line, have led to concerns about subpar sales performance and potential clinical failures across various indications. Additionally, several risks, including safety issues, efficacy concerns, increased competition, and regulatory uncertainties, further contribute to the company's precarious financial trajectory.

Novocure (NVCR) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 17% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 6 analysts, Novocure (NVCR) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.